Progenitor, Inc.

Vistagen Therapeutics, Inc.

Vanderbilt University

Indevus Pharmaceuticals, Inc.

Interneuron Pharmaceuticals, Inc.

Valentis, Inc.

H Ralph Snodgrass

Thomas Joel Zupancic

Joseph Cioffi

Alan Wayne Shafer

Allen E Cato

Jack S Hicklin

Thomas Quertermous

Brigid L Hogan

Bridgid Hogan

Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction.

Dosage forms and therapeutic uses of L-4-chlorokynurenine

Compositions of L-4-chlorokynurenic are provided, as are methods for the treatment of neurological dysfunction.

Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurologica dyslinction.

Dosage forms and therapeutic uses L-4-chlorokynurenine

This invention provides methods and systems for identifying and typing toxicity of chemical compositions, as well as for screening new compositions for toxicity. The invention involves detecting alterations in gene or protein expression and hence establishing molecular profiles in isolated mammalian LSCs contacted with various chemical compositions of known and unknown toxicities, and correlating the molecular profiles with toxicities of the chemical compositions.

Toxicity typing using liver stem cells

The present invention relates to a member of a novel gene family referred to as developmentally-regulated endothelial cell locus-1 (del-1). In particularly, the invention related to del-1 nucleotide sequences, Del-1 amino acid sequences, methods of expressing a functional gene product, and methods of using the gene and gene product. Since del-1 is expressed in endothelial cells and certain cancer cells, it may be useful as an endothelial cell and tumor marker. In addition, anti-Del-1 antibodies for immunological assessment of Del-1 protein expression as well as for inhibiting or stimulating Del-1 function are provided.

Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1

The present invention relates to a variant from of the receptor for the obese gene product. In particular, the invention relates to methods of detecting this receptor variant in cells and tissues of obese individuals. In addition, it relates to methods of inhibiting or down regulating expression of this variant in cells to augment their responsiveness to weight regulation by leptin as well as methods of using compounds to directly activate signal transduction pathways associated with this ligand-receptor system. In addition, the invention relates to identifying compounds capable of supplementing biological activity of leptin on cells expressing a leptin receptor variant.

Methods for identifying compounds capable of supplementing the biological activity of leptin

The present invention relates to methods for using various forms of a novel receptor expressed by hematopoietic and endothelial cells. An additional variant form of this receptor has been detected in brain cells and shown to bind to the obese gene product, leptin. Therefore, leptin may be used to stimulate the growth and development of receptor-positive hematopoietic and endothelial cells in vitro and in vivo. In addition, this receptor is selectively expressed in hematopoietic progenitor cells with long-term repopulating potential. Thus, agents that specifically bind to this receptor may be used to identify and isolate progenitor cells for a variety of clinical applications.

Methods for using the obese product to stimulate hematopoietic development

The present invention relates to a novel member of the hematopoietin receptor family, herein referred to as Hu-B1.219. In particular, the invention relates to nucleotide sequences and expression vectors encoding Hu-B1.219 gene product. Genetically engineered host cells that express the Hu-B1.219 coding sequence may be used to evaluate and screen for ligands or drugs involved in Hu-B1.219 interaction and regulation. Since Hu-B1.219 expression has been detected in certain human fetal tissues and cancer cells, molecular probes designed from its nucleotide sequence may be useful for prenatal testing and cancer diagnosis.

Methods of screening for ligands of human hemetopoietin receptor HU-B1.219

The present invention relates to a variant form of the receptor for the obese gene product. In particular, the invention relates to methods of detecting this receptor variant in cells and tissues of obese individuals. In addition, it relates to methods of inhibiting or down-regulating expression of this variant in cells to augment their responsiveness to weight regulation by leptin as well as methods of using compounds to directly activate signal transduction pathways associated with this ligand-receptor system.

Detection of a leptin receptor variant and methods for regulating obesity

Methods for using the obese gene and its gene product to stimulate hematopoietic development

Antibodies specific for Hu-B1.219, a novel hematopoietin receptor

The present invention relates to variant forms of the receptor for the obese gene product. In particular, the invention relates to methods of detecting receptor variants in the reproductive organs for the diagnosis of the cause of infertility. In addition, it relates to methods of inhibiting or down-regulating expression of defective variants in cells to augment their responsiveness to regulation by leptin as well as methods of using compounds to directly activate signal transduction pathways associated with this ligand-receptor system to improve fertility.

Growing community of inventors

Powell, OH, United States of America

H Ralph Snodgrass